Oxford Biomedica signs licence agreement for LentiVector Platform

John Dawson CBE, CEO of Oxford Biomedica
John Dawson

Oxford Biomedica plc, the leading gene and cell therapy group, has signed a new License and Supply Agreement (LSA) with Cabaletta Bio, Inc. , a Philadelphia, USA-based clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases.

Oxford biomedical’s LentiVector platform is the first commercially approved lentiviral based gene delivery system. It is recognised as a leading solution by multiple companies.

The platform enables the successful development of breakthrough gene and cell-based medicines by the company and its partners.

Lentiviral vectors are advantageous for a number of reasons. They can deliver large therapeutic payloads (up to 10kb) into target cells. Permanent modification of dividing and non-dividing cells is achieved through gene integration and long-term expression. Their lack of pre-existing immunity makes them safe to use.

Oxford Biomedica is also celebrating its CEO, John Dawson, being awarded a CBE in the Queen’s New Year Honours List for services to UK Life Science.

Dr. Roch Doliveux, Chair of Oxford Biomedica, said: “I warmly congratulate John for receiving this thoroughly deserved recognition. Thanks to his foresight, Oxford Biomedica has grown to become a world leader in cell and gene therapy, helping society during the COVID-19 pandemic and beyond. I and the entire Board are extremely grateful to John for his warm and resilient leadership and having built Oxford Biomedica as a world leader in viral vectors for cell and gene therapy, enabling so many lives to be saved.”

In September last year, Oxford Biomedica announced that revenues increased by a record 139 per cent to £81.3 million. It also announced that Serum Life Sciences Ltd, a subsidiary company of Serum Institute of India Pvt Ltd has agreed to invest just over £50 million in the Group.

The investment will be used to fund the development of the fallow area at Oxbox, the Group’s 84,000 sq. ft manufacturing facility based in Oxford, UK, into a flexible advanced manufacturing space and the validation of several independent cGMP suites, expected to come online in mid-2023. (cGMP refers to the Current Good Manufacturing Practice).

The leading gene and cell therapy group, which has been manufacturing the AstraZeneca vaccine at its Oxford facility all last year, is continuing with its large-scale commercial, running three manufacturing suites at 1000L scale.

On announcing the results last year, John Dawson, Oxford Biomedica’s Chief Executive Officer, said: “Everyone at Oxford Biomedica can be truly proud of what they have continued to achieve in 2021. The tireless commitment of the whole team has helped to save thousands of lives, in line with our mission, whilst gaining global recognition for our role in the fight against COVID-19. The exceptional financial results that we have reported reflect our strong progress across the business as we continue to demonstrate our world leading expertise in gene and cell therapy. As we move from strength to strength, and with rapid growth in the cell and gene therapy market, we are in a great position to maximise on the opportunities ahead, both in lentiviral vectors as well as other viral vector types and look forward to the remainder of 2021 and beyond with considerable confidence.”